KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.
“We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “We are resolute in our commitment to contribute to the global effort to relieve the burden of this pandemic on patients, health care systems and communities.”
Due to the discontinuation, the company will record a charge in the fourth quarter of 2020. The charge will be included in Merck’s generally accepted accounting principles (GAAP) results, but will not impact non-GAAP results.
- Do You Accept a 35% Higher Chance of Dying Today? Well Then I Have Life-or- Death News For You.
- THAILAND DECLARES DEATH CON 3 ON PFIZER
- On The Brink Of WW3 (Updates)
- ‘Climate change is accelerating’: Mount Washington as cold as Mars (Coldest wind chill ever recorded)
- Don’t Be Stupid – The U.S. Economy Actually LOST 2.5 Million Jobs Last Month
- Ukraine is About to Get Shafted
- Global Leaders Dump The Dollar – Why Now?
- The balloon is most likely a hoax intended to divert attention away from the Project Veritas Pfizer BUST.
- SOMETHING HUGE IS COMING
- U.S. Senator Mike Lee Threatens Japan’s Prime Minister, Gives February 28, 2023 Deadline